cyclosporine

(redirected from cyclosporines)
Also found in: Dictionary.

cyclosporine

 [si″klo-spōr´in]
a cyclic peptide from an extract of soil fungi, an inhibitor of t cell function; used as an immunosuppressant to prevent and treat rejection in organ transplant recipients and to treat severe psoriasis and as a disease-modifying antirheumatic drug.

cy·clo·spor·ine

(sī'klō-spōr'ēn),
A cyclic oligopeptide immunosuppressant produced by the fungus Tolypocladium inflatum Gams; used to inhibit organ transplant rejection.

cyclosporine

/cy·clo·spor·ine/ (-spor´ēn) a cyclic peptide from an extract of soil fungi that selectively inhibits T cell function; used as an immunosuppressant to prevent rejection in organ transplant recipients and to treat severe psoriasis and severe rheumatoid arhtritis.

cyclosporine

(sī′klə-spôr′ēn, -ĭn) also

cyclosporin

(-ĭn)
n.
An immunosuppressive drug obtained from certain soil fungi, used mainly to prevent the rejection of transplanted organs.

cyclosporine

Immunology A cyclic undecapeptide, which induces potent T-cell immunosuppression; cyclosporine mitigates GVHD, allograft rejection, ulcerative colitis, autoimmune disease, schistosomiasis; it may be of use in aplastic anemia, in combination with antilymphocyte globulin and methylprednisone for psoriasis Adverse effects Nephrotoxicity, HTN, neurotoxicity–eg, tremor, seizures, encephalopathy, headache, coma, hyperlipidemia, hyperkalemia, hypomagnesemia, HTN, anemia, anaphylaxis, nausea, paresthesias, ↑ EBV, lymphoma, pseudolymphoma, fluid retention, thromboses, hirsutism, liver toxicity Lab ↑ Creatinine, ↑ uric acid, ↑ BR, ↑ cholesterol. Cf Tacrolimus.

cy·clo·spor·ine

(sī'klō-spōr'ēn)
A cyclic oligopeptide immunosuppressant produced by the fungus Tolypocladium inflatum Gams; used to inhibit organ transplant rejection.

ciclosporin (cyclosporine) 

An immunosuppressant used in the treatment of the ocular manifestation of autoimmune diseases, uveitis, scleritis, keratoconjunctivitis sicca, ligneous conjunctivitis, and to prevent rejection of corneal grafts, etc. It is believed to exert its immunosuppressive effect by inhibiting the activation of cytotoxic T-lymphocytes. See immunosuppressants.

cy·clo·spor·ine

(sī'klō-spōr'ēn)
A cyclic oligopeptide immunosuppressant used to inhibit organ transplant rejection.

cyclosporine (sī´klōspor´ēn),

n brand name: Sandimmune;
drug class: immunosuppressant;
action: produces immunosuppression by inhibiting lymphocytes;
uses: to prevent rejection of tissues and/or organ transplants.

cyclosporine

a neutral cyclic peptide, the major metabolic product of the fungus Tolypocladium inflatum; a specific suppressor of the T lymphocyte response, important in tissue transplantation.
References in periodicals archive ?
Eli Lilly manufactured the exhibit batch used in SangStat's pivotal CYCLOSPORINE bioequivalence trials.
SangStat recently completed pivotal bioequivalence trials demonstrating that SangStat's CYCLOSPORINE formulation is bioequivalent to Neoral.
based in Hong Kong, will register and market SangStat's CYCLOSPORINE in their respective territories.
2, 1997--SangStat, The Transplant Company(R), (NASDAQ:SANG) today announced the signing of an exclusive agreement with Amgen (NASDAQ:AMGN) for the registration, marketing and distribution of SangStat's proprietary CYCLOSPORINE product candidate in select territories in the Asia/Pacific rim.
Jens Eckstein, Enanta's Director, Lead Discovery, presented new research on a novel class of cyclosporine analogs that were discovered at Enanta with improved toxicity profiles, and have potential for the improved treatment of diseases such as transplantation, psoriasis, and asthma.
Eckstein's presentation will discuss Enanta's most recent cyclosporine research that includes the development of new cyclosporine analogs, EP-314 and EP-012637, which, when converted into non-toxic metabolites, prove to be distinct from Cyclosporine A and its metabolites that have limited therapeutic potential due to kidney toxicity.
Other factors that could cause actual results to differ materially include, without limitation, uncertainty related to the current or future manufacturing of commercial quantities of CYCLOSPORINE and THYMOGLOBULIN on commercially favorable terms, adequate and continuous supply of bulk CYCLOSPORINE drug substance, market acceptance, profitability, competition and potential litigation.
Data on several product candidates and technologies will be presented including CYCLOSPORINE, THYMOGLOBULIN(R), CELSIOR(R) and ALLOTRAP(R) peptides.
A Program to Develop a Cyclosporine Formulation that is Bioequivalent to Neoral; Timothy Schroeder, et al.
Both Sang-35, a Novel Cyclosporine Formulation, and Neoral Result in Low Pharmacokinetic Variability in Healthy Volunteers; Philippe Pouletty, et al.
Under current FDA regulations and policy, a cyclosporine formulation that is shown to be bioequivalent to Neoral may be approved without the need to duplicate safety and efficacy trials.
Neoral, an improved formulation of cyclosporine with increased bioavailability, was launched first in Europe in 1994 and then in the United States in September 1995.